Custom service
Binding Capacities of Immunoglobulin Proteins
Affinity, avidity and stoichiometry, measured rather than assumed.
Binding data are often reported as a single number, which is a convenient fiction. A KD describes an equilibrium reached under specific conditions; it says nothing about how fast the complex forms, whether the antibody can bind two antigens simultaneously, or whether the interaction survives the buffer an assay actually uses. Characterisation is the process of measuring the properties that matter for a given application.
Surface plasmon resonance and biolayer interferometry give kinetics directly: association and dissociation rate constants, from which KD is calculated. SPR is the more sensitive and more demanding technique, requiring careful immobilisation and reference channel subtraction; BLI is more tolerant of crude samples and easier to run in parallel, which makes it useful for ranking clones early.
Avidity is measured separately. A bivalent IgG binding a surface-immobilised antigen shows an apparent affinity far higher than the intrinsic affinity of one arm, because the second arm binds intramolecularly after the first releases. Running the same experiment with a Fab fragment gives the intrinsic value, and the ratio between the two quantifies the avidity gain — a number that predicts performance in a sandwich assay better than KD alone.
Service Highlights
Where it fits
Characterisation is required whenever binding data will be used to make a decision: choosing between clones, setting an assay cut-off, supporting a patent or a regulatory filing, or predicting whether an antibody will survive a wash step in a lateral flow strip.
It is over-specified for early screening, where a simple ELISA ranking is faster and cheaper. It is also of limited value for polyclonals, where a single KD misrepresents a heterogeneous population.
Documentation and QC
Reports include sensorgrams for every concentration, the fitting model, chi-squared and Rmax values, and the buffer composition used. Active concentration is reported alongside A280 concentration, because the difference between them is often the reason an assay underperforms.
Frequently asked questions
Which is better, SPR or BLI?
SPR gives better signal-to-noise and is preferred for weak interactions and for precise kinetics. BLI tolerates crude samples and runs in parallel, which makes it better for screening. We use both and report which was used.
Why is my KD different from the published value?
Because KD depends on buffer, temperature, immobilisation density and the valency of the immobilised ligand. A value measured at pH 7.4 in PBS will not match one measured at pH 6.0, and neither is wrong.
Can you measure binding in serum?
Yes, with a reference channel and a matched blank matrix. Non-specific binding rises, so the assay is designed with a blocking strategy and the matrix effect is reported.
Tell us what decision the data will support. Measuring KD is easy; measuring the property that predicts your assay's performance takes a deliberate design.
Service Highlights
- Kinetics, not just affinity. Ka and kd reported separately, since a slow-on/slow-off antibody and a fast-on/fast-off antibody with the same KD behave very differently in a wash-based assay.
- Intrinsic versus apparent affinity. Fab and IgG measured side by side to separate monovalent affinity from bivalent avidity.
- Epitope binning. Pairwise competition in a BLI or SPR format establishes which antibodies can form a sandwich pair before an assay is built around them.
- Buffer and temperature control. Measurements run at the pH and temperature of the intended assay, with the effect of each reported.
- Polyclonal characterisation. Apparent affinity distribution rather than a single KD, since a polyclonal has no single binding constant.
- Concentration and stoichiometry. Active antibody concentration determined by binding-site titration, which is often far below the A280 value.
How the work runs
Assay design
The question determines the method: ranking clones, measuring true affinity, finding a sandwich pair, or quantifying active concentration.
Surface preparation
Antigen immobilised by amine coupling, streptavidin capture of biotinylated antigen, or protein A capture of the antibody; reference surfaces prepared for each.
Titration
A concentration series spanning at least ten-fold above and below the expected KD, with replicates and blank injections.
Kinetic analysis
Sensorgrams fitted to a 1:1 model first; heterogeneity, mass transport or bivalent models applied only where the data require them.
Avidity and binning
Fab versus IgG comparison for avidity, and pairwise injection for epitope bins.
Reporting
ka, kd, KD, Rmax and chi-squared for every interaction, with the model stated and the raw sensorgrams supplied.
Specifications & timeline
- Methods
- SPR, BLI, ELISA — ITC and DSF optional
- Kd range
- pM–µM — with kinetic constants
- Timeline
- 2–3 weeks — per panel
- Methods
- SPR (Biacore-type), BLI (Octet-type), ELISA, ITC, DSF, SEC-MALS
- KD range
- 10⁻¹² to 10⁻⁵ M, with ka and kd reported separately
- Kinetic models
- 1:1 Langmuir as default; bivalent, heterogeneous and mass-transport models where justified
- Active concentration
- Binding-site titration by SPR, reported alongside A280
- Binning
- Pairwise competition, output as a bin matrix
- Timeline
- 2–3 weeks per panel of up to 20 antibodies
- Deliverables
- Sensorgrams, fitted constants, chi-squared and Rmax, bin matrix, buffer conditions
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.